Oral administration of glycine increases extracellular serotonin but not dopamine in the prefrontal cortex of rats

Psychiatry and Clinical Neurosciences

Volumn 65, Issue 2, 2011, Pages 142-149

  Bannai, Makoto ^a   Kawai, Nobuhiro ^a   Nagao, Kenji ^a   Nakano, Sayako ^a   Matsuzawa, Daisuke ^b   Shimizu, Eiji ^b  

^a AJINOMOTO CO INC   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

d serine; glycine; schizophrenia; serotonin; sleep

Indexed keywords

DEXTRO SERINE; DOPAMINE; GLYCINE; SERINE; SEROTONIN;

ANIMAL EXPERIMENT; ARTICLE; DOPAMINE BRAIN LEVEL; EXTRACELLULAR SPACE; MALE; MICRODIALYSIS; NONHUMAN; PREFRONTAL CORTEX; RAT; SEROTONIN BRAIN LEVEL; STEREOTACTIC PROCEDURE;

ADMINISTRATION, ORAL; ANIMALS; DOPAMINE; EXTRACELLULAR SPACE; GLYCINE; MALE; MICRODIALYSIS; PREFRONTAL CORTEX; RATS; RATS, WISTAR; SERINE; SEROTONIN;

EID: 79952966447     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2010.02181.x     Document Type: Article

References (43)

1. Johnson JW, Ascher P,. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 1987; 325: 529-531. (Pubitemid 17056733)
2. Leeson PD, Iversen LL,. The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential. J. Med. Chem. 1994; 37: 4053-4067. (Pubitemid 24379693)
3. Inagawa K, Hiraoka T, Kohda T, Yamadera W, Takahashi M,. Subjective effects of glycine ingestion before bedtime on sleep quality. Sleep Biol. Rhythms 2006; 4: 75-77. (Pubitemid 43733236)
4. Yamadera W, Inagawa K, Chiba S, Bannai M, Takahashi M, Nakayama K,. Glycine ingestion improves subjective sleep quality in human volunteers, correlating with polysomnographic changes. Sleep Biol. Rhythms 2007; 5: 126-131. (Pubitemid 46443668)
5. Darracq L, Gervasoni D, Souliere F, et al,. Effect of strychnine on rat locus coeruleus neurones during sleep and wakefulness. Neuroreport 1996; 8: 351-355. (Pubitemid 126785587)
6. Monti JM, Jantos H, Giuseppe Di Giovann VDM, Ennio E,. The roles of dopamine and serotonin, and of their receptors, in regulating sleep and waking. Prog. Brain Res. 2008; 172: 625-646.
7. Tuominen HJ, Tiihonen J, Wahlbeck K,. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr. Res. 2005; 72: 225-234. (Pubitemid 39550993)
8. Hashimoto K, Fukushima T, Shimizu E, et al,. Decreased serum levels of d-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch. Gen. Psychiatry 2003; 60: 572-576. (Pubitemid 36682314)
9. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M,. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch. Gen. Psychiatry 1999; 56: 29-36. (Pubitemid 29055047)
10. Javitt DC, Silipo G, Cienfuegos A, et al,. Adjunctive high-dose glycine in the treatment of schizophrenia. Int. J. Neuropsychopharmacol. 2001; 4: 385-391. (Pubitemid 33151682)
11. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP,. Amelioration of negative symptoms in schizophrenia by glycine. Am. J. Psychiatry 1994; 151: 1234-1236. (Pubitemid 24240973)
12. Shimizu E, Hashimoto K, Ochi S, et al,. Posterior cingulate gyrus metabolic changes in chronic schizophrenia with generalized cognitive deficits. J. Psychiatr. Res. 2007; 41: 49-56. (Pubitemid 44708200)
13. Davis KL, Kahn RS, Ko G, Davidson M,. Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry 1991; 148: 1474-1486.
14. Dean B, Hayes W,. Decreased frontal cortical serotonin2A receptors in schizophrenia. Schizophr. Res. 1996; 21: 133-139. (Pubitemid 26298405)
15. Lewis R, Kapur S, Jones C, et al,. Serotonin 5-HT2 receptors in schizophrenia: a PET study using [18F]setoperone in neuroleptic-naive patients and normal subjects. Am. J. Psychiatry 1999; 156: 72-78. (Pubitemid 29034882)
16. US National Institutes of Health. Guide for the Care and Use of Laboratory Animals. NIH Publication No 85-23, revised 1996.
17. Paxinos G, Watson C,. The Rat Brain in Stereotaxic Coordinates. Academic Press, San Diego, CA, 2005.
18. Noguchi Y, Zhang QW, Sugimoto T, et al,. Network analysis of plasma and tissue amino acids and the generation of an amino index for potential diagnostic use. Am. J. Clin. Nutr. 2006; 83: 513S-519S. (Pubitemid 44713229)
19. Gannon MC, Nuttall JA, Nuttall FQ,. The metabolic response to ingested glycine. Am. J. Clin. Nutr. 2002; 76: 1302-1307. (Pubitemid 35416566)
20. Kanahara N, Shimizu E, Ohgake S, et al,. Glycine and D: -serine, but not D: -cycloserine, attenuate prepulse inhibition deficits induced by NMDA receptor antagonist MK-801. Psychopharmacology (Berl.) 2008; 198: 363-374.
21. D'Souza DC, Charney D, Krystal J,. Glycine site agonists of the NMDA receptor: a review. CNS Drug Rev. 1995; 1: 227-260.
22. Matsui T, Sekiguchi M, Hashimoto A, Tomita U, Nishikawa T, Wada K,. Functional comparison of d-serine and glycine in rodents: the effect on cloned NMDA receptors and the extracellular concentration. J. Neurochem. 1995; 65: 454-458.
23. Akaike N, Kaneda M,. Glycine-gated chloride current in acutely isolated rat hypothalamic neurons. J. Neurophysiol. 1989; 62: 1400-1409. (Pubitemid 20018094)
24. Becquet D, Hery M, Deprez P, et al,. N-methyl-D-aspartic acid/glycine interactions on the control of 5-hydroxytryptamine release in raphe primary cultures. J. Neurochem. 1993; 61: 1692-1697. (Pubitemid 23317191)
25. Becquet D, Hery M, Francois-Bellan AM, et al,. Glutamate, GABA, glycine and taurine modulate serotonin synthesis and release in rostral and caudal rhombencephalic raphe cells in primary cultures. Neurochem. Int. 1993; 23: 269-283.
26. Tanaka J, Miyakubo H, Kawakami A, Hayashi Y, Nomura M,. Involvement of NMDA receptor mechanisms in the modulation of serotonin release in the lateral parabrachial nucleus in the rat. Brain Res. Bull. 2006; 71: 311-315. (Pubitemid 44750448)
27. Shearman E, Rossi S, Szasz B, et al,. Changes in cerebral neurotransmitters and metabolites induced by acute donepezil and memantine administrations: a microdialysis study. Brain Res. Bull. 2006; 69: 204-213. (Pubitemid 43375876)
28. Smiley JF, Goldman-Rakic PS,. Serotonergic axons in monkey prefrontal cerebral cortex synapse predominantly on interneurons as demonstrated by serial section electron microscopy. J. Comp. Neurol. 1996; 367: 431-443. (Pubitemid 26107129)
29. Zhong P, Yuen EY, Yan Z,. Modulation of neuronal excitability by serotonin-NMDA interactions in prefrontal cortex. Mol. Cell. Neurosci. 2008; 38: 290-299.
30. Hernandes MS, de Magalhaes L, Troncone LR,. Glycine stimulates the release of labeled acetylcholine but not dopamine nor glutamate from superfused rat striatal tissue. Brain Res. 2007; 1168: 32-37. (Pubitemid 47320629)
31. Bennett S, Gronier B,. Modulation of striatal dopamine release in vitro by agonists of the glycineB site of NMDA receptors; interaction with antipsychotics. Eur. J. Pharmacol. 2005; 527: 52-59. (Pubitemid 41745151)
32. Krystal JH, Anand A, Moghaddam B,. Effects of NMDA receptor antagonists: implications for the pathophysiology of schizophrenia. Arch. Gen. Psychiatry 2002; 59: 663-664. (Pubitemid 34747249)
33. Moghaddam B, Adams B, Verma A, Daly D,. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 1997; 17: 2921-2927. (Pubitemid 27155025)
34. Jentsch JD, Tran A, Le D, Youngren KD, Roth RH,. Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsychopharmacology 1997; 17: 92-99.
35. Felton TM, Kang TB, Hjorth S, Auerbach SB,. Effects of selective serotonin and serotonin/noradrenaline reuptake inhibitors on extracellular serotonin in rat diencephalon and frontal cortex. Naunyn Schmiedebergs Arch. Pharmacol. 2003; 367: 297-305. (Pubitemid 36408012)
36. Portas CM, Bjorvatn B, Fagerland S, et al,. On-line detection of extracellular levels of serotonin in dorsal raphe nucleus and frontal cortex over the sleep/wake cycle in the freely moving rat. Neuroscience 1998; 83: 807-814. (Pubitemid 28068901)
37. Idzikowski C, Mills FJ, James RJ,. A dose-response study examining the effects of ritanserin on human slow wave sleep. Br. J. Clin. Pharmacol. 1991; 31: 193-196.
38. Dugovic C, Wauquier A, Leysen JE, Marrannes R, Janssen PA,. Functional role of 5-HT2 receptors in the regulation of sleep and wakefulness in the rat. Psychopharmacology (Berl.) 1989; 97: 436-442. (Pubitemid 19102542)
39. Kantor S, Jakus R, Bodizs R, Halasz P, Bagdy G,. Acute and long-term effects of the 5-HT2 receptor antagonist ritanserin on EEG power spectra, motor activity, and sleep: changes at the light-dark phase shift. Brain Res. 2002; 943: 105-111. (Pubitemid 34671178)
40. Popa D, Lena C, Fabre V, et al,. Contribution of 5-HT2 receptor subtypes to sleep-wakefulness and respiratory control, and functional adaptations in knock-out mice lacking 5-HT2A receptors. J. Neurosci. 2005; 25: 11231-11238. (Pubitemid 43083697)
41. Breier A,. Serotonin, schizophrenia and antipsychotic drug action. Schizophr. Res. 1995; 14: 187-202.
42. Abi-Dargham A,. Alterations of serotonin transmission in schizophrenia. Int. Rev. Neurobiol. 2007; 78: 133-164.
43. Abi-Dargham A, Laruelle M, Aghajanian GK, Charney D, Krystal J,. The role of serotonin in the pathophysiology and treatment of schizophrenia. J. Neuropsychiatry Clin. Neurosci. 1997; 9: 1-17. (Pubitemid 27075408)